0000891293-22-000047.txt : 20221006 0000891293-22-000047.hdr.sgml : 20221006 20221006162045 ACCESSION NUMBER: 0000891293-22-000047 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221004 FILED AS OF DATE: 20221006 DATE AS OF CHANGE: 20221006 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: KIRSKE DAVID CENTRAL INDEX KEY: 0001276750 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-28386 FILM NUMBER: 221298400 MAIL ADDRESS: STREET 1: C/O CTI BIOPHARMA CORP. STREET 2: 3101 WESTERN AVE., SUITE 600 CITY: SEATTLE STATE: WA ZIP: 98121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CTI BIOPHARMA CORP CENTRAL INDEX KEY: 0000891293 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 911533912 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3101 WESTERN AVENUE STREET 2: SUITE 800 CITY: SEATTLE STATE: WA ZIP: 98121 BUSINESS PHONE: 2062827100 MAIL ADDRESS: STREET 1: 3101 WESTERN AVENUE STREET 2: SUITE 800 CITY: SEATTLE STATE: WA ZIP: 98121 FORMER COMPANY: FORMER CONFORMED NAME: CELL THERAPEUTICS INC DATE OF NAME CHANGE: 19960321 4 1 primary_doc.xml PRIMARY DOCUMENT X0306 4 2022-10-04 0 0000891293 CTI BIOPHARMA CORP CTIC 0001276750 KIRSKE DAVID C/O CTI BIOPHARMA CORP. 3101 WESTERN AVE., SUITE 800 SEATTLE WA 98121 0 1 0 0 EVP, Chief Financial Officer common stock 2022-10-04 4 M 0 1400 0.9489 A 18313 D common stock 2022-10-04 4 S 0 1400 6.25 D 16913 D common stock 2022-10-04 4 M 0 100 0.9489 A 17013 D common stock 2022-10-04 4 S 0 100 6.26 D 16913 D common stock 2022-10-04 4 M 0 609 0.9489 A 17522 D common stock 2022-10-04 4 S 0 609 6.27 D 16913 D Non-Qualified Stock Option (right to buy) 0.9489 2022-10-04 4 M 0 1400 0 D 2029-02-19 Common Stock 1400 324967 D Non-Qualified Stock Option (right to buy) 0.9489 2022-10-04 4 M 0 100 0 D 2029-02-19 Common Stock 100 324867 D Non-Qualified Stock Option (right to buy) 0.9489 2022-10-04 4 M 0 609 0 D 2029-02-19 Common Stock 609 324258 D This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person. One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022. David Kirske 2022-10-06